Sven Perner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2609786/publications.pdf

Version: 2024-02-01

150	21,338	25034 57	9589 142
papers	citations	h-index	g-index

152	152	152	26775
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses ItsÂPro-Oncogenic Effects in Prostate Cancer. American Journal of Pathology, 2022, 192, 813-823.	3.8	4
2	Targeting cyclin-dependent kinase 7â€"association between CDK7 and pMED1 expression in prostate cancer tissue. Carcinogenesis, 2022, 43, 779-786.	2.8	4
3	Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 380.e11-380.e18.	1.6	1
4	TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC. Journal of Personalized Medicine, 2022, 12, 991.	2.5	6
5	Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative Colitis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 229-250.	4.5	27
6	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. European Urology, 2021, 79, 519-529.	1.9	30
7	Novel approaches to target the microenvironment of bone metastasis. Nature Reviews Clinical Oncology, 2021, 18, 488-505.	27.6	91
8	Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. Carcinogenesis, 2021, 42, 1475-1484.	2.8	5
9	CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia. Human Pathology, 2021, 117, 60-67.	2.0	3
10	Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. Clinical Cancer Research, 2021, 27, 632-644.	7.0	49
11	Chromothripsis followed by circular recombination drives oncogene amplification in human cancer. Nature Genetics, 2021, 53, 1673-1685.	21.4	61
12	The new ISUP 2014/WHO 2016 prostate cancer grade group system: first rÃ©sumÃ© 5Âyears after introduction and systemic review of the literature. World Journal of Urology, 2020, 38, 657-662.	2.2	12
13	Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 261-271.	2.8	15
14	Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer. International Journal of Cancer, 2020, 146, 577-588.	5.1	23
15	Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 561-568.	2.8	21
16	GC1qR Cleavage by Caspase-1 Drives Aerobic Glycolysis in Tumor Cells. Frontiers in Oncology, 2020, 10, 575854.	2.8	15
17	Lung cancer biomarker testing: perspective from Europe. Translational Lung Cancer Research, 2020, 9, 887-897.	2.8	25
18	CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC. International Journal of Molecular Sciences, 2020, 21, 5508.	4.1	6

#	Article	IF	Citations
19	Histomorphological analysis of false positive PI-RADS 4 and 5 lesions. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 636.e7-636.e12.	1.6	7
20	A randomized trial (RAREST-01) comparing MepitelÂ® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). Radiotherapy and Oncology, 2019, 139, 79-82.	0.6	25
21	TRIM24 as an independent prognostic biomarker for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 576.e1-576.e10.	1.6	18
22	KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells. Nature Structural and Molecular Biology, 2019, 26, 361-371.	8.2	57
23	Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. Frontiers in Medicine, 2019, 6, 27.	2.6	54
24	In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2493-2496.	1.3	0
25	DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271.	7.7	59
26	Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma. American Journal of Pathology, 2018, 188, 72-83.	3.8	22
27	Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. Frontiers in Oncology, 2018, 8, 623.	2.8	108
28	A mechanistic classification of clinical phenotypes in neuroblastoma. Science, 2018, 362, 1165-1170.	12.6	213
29	Fountain of youth for squamous cell carcinomas? On the epigenetic age of nonâ€small cell lung cancer and corresponding tumorâ€free lung tissues. International Journal of Cancer, 2018, 143, 3061-3070.	5.1	8
30	Prominent Oncogenic Roles of EVI1 in Breast Carcinoma. Cancer Research, 2017, 77, 2148-2160.	0.9	36
31	Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy. Oncology Letters, 2017, 13, 22-28.	1.8	15
32	ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. Cancer Research, 2017, 77, 3040-3056.	0.9	81
33	Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer. International Journal of Cancer, 2017, 141, 1643-1653.	5.1	21
34	Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer. Clinical Cancer Research, 2017, 23, 1829-1840.	7.0	74
35	Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. International Journal of Molecular Sciences, 2017, 18, 7.	4.1	36
36	Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. Frontiers in Medicine, 2017, 4, 30.	2.6	13

#	Article	IF	Citations
37	Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups. Frontiers in Medicine, 2017, 4, 157.	2.6	21
38	IL-4/5 signalling plays an important role during Litomosoides sigmodontis infection, influencing both immune system regulation and tissue pathology in the thoracic cavity. International Journal for Parasitology, 2017, 47, 951-960.	3.1	16
39	MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. Oncotarget, 2017, 8, 7964-7976.	1.8	16
40	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget, 2017, 8, 14719-14735.	1.8	21
41	IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2. American Journal of Pathology, 2016, 186, 974-984.	3.8	17
42	Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Targeted Oncology, 2016, 11, 631-642.	3.6	10
43	PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. OncoImmunology, 2016, 5, e1131379.	4.6	94
44	<scp>NOTCH</scp>, <scp>ASCL1</scp>, p53 and <scp>RB</scp> alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. International Journal of Cancer, 2016, 138, 927-938.	5.1	143
45	Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner. Molecular Cancer Research, 2016, 14, 1110-1123.	3.4	18
46	Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib. International Journal of Cancer, 2016, 139, 2359-2369.	5.1	27
47	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somaticTMPRSS2:ERGfusion status. Human Molecular Genetics, 2016, 25, ddw349.	2.9	8
48	Web-TCGA: an online platform for integrated analysis of molecular cancer data sets. BMC Bioinformatics, 2016, 17, 72.	2.6	140
49	Exome sequencing identifies potential novel candidate genes in patients with unexplained colorectal adenomatous polyposis. Familial Cancer, 2016, 15, 281-288.	1.9	40
50	Low-levelAPCmutational mosaicism is the underlying cause in a substantial fraction of unexplained colorectal adenomatous polyposis cases. Journal of Medical Genetics, 2016, 53, 172-179.	3.2	51
51	Assembly of methylated KDM1A and CHD1 drives androgen receptorâ€“dependent transcription and translocation. Nature Structural and Molecular Biology, 2016, 23, 132-139.	8.2	70
52	The activation of OR51E1 causes growth suppression of human prostate cancer cells. Oncotarget, 2016, 7, 48231-48249.	1.8	53
53	Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. Oncotarget, 2016, 7, 23043-23055.	1.8	24
54	MERTK as a novel therapeutic target in head and neck cancer. Oncotarget, 2016, 7, 32678-32694.	1.8	17

#	Article	IF	Citations
55	Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. Translational Oncology, 2015, 8, 487-496.	3.7	9
56	AIM2 Drives Joint Inflammation in a Self-DNA Triggered Model of Chronic Polyarthritis. PLoS ONE, 2015, 10, e0131702.	2.5	85
57	FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clinical Cancer Research, 2015, 21, 4356-4364.	7.0	75
58	Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer. Pathology, 2015, 47, 629-636.	0.6	22
59	Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer. Modern Pathology, 2015, 28, 138-145.	5.5	45
60	Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. British Journal of Haematology, 2015, 169, 415-422.	2.5	66
61	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	27.8	1,634
62	Identification of novel differentially expressed lncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling. Genomics Data, 2015, 5, 173-175.	1.3	32
63	Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder. Scandinavian Journal of Urology, 2015, 49, 382-387.	1.0	11
64	Clinical and Molecular Implications of MED15 in Head and Neck Squamous Cell Carcinoma. American Journal of Pathology, 2015, 185, 1114-1122.	3.8	21
65	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature, 2015, 526, 700-704.	27.8	478
66	Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget, 2015, 6, 35542-35555.	1.8	60
67	Molecular and functional interactions between AKT and SOX2 in breast carcinoma. Oncotarget, 2015, 6, 43540-43556.	1.8	37
68	Survival According to BRAF-V600 Tumor Mutations â€“ An Analysis of 437 Patients with Primary Melanoma. PLoS ONE, 2014, 9, e86194.	2.5	42
69	Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma. Molecular Cancer Research, 2014, 12, 1460-1469.	3.4	38
70	FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. Clinical Cancer Research, 2014, 20, 3299-3309.	7.0	141
71	Disruption of the PRKCDâ€“FBXO25â€“HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nature Medicine, 2014, 20, 1401-1409.	30.7	50
72	Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 113, 209-217.	2.5	26

#	Article	IF	Citations
73	MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castrationâ€resistant prostate cancer. International Journal of Cancer, 2014, 135, 19-26.	5.1	24
74	GNAS Sequencing Identifies IPMN-specific Mutations in a Subgroup of Diminutive Pancreatic Cysts Referred to as â€œIncipient IPMNsâ€. American Journal of Surgical Pathology, 2014, 38, 360-363.	3.7	52
75	Single-Cell Genetic Analysis Reveals Insights into Clonal Development of Prostate Cancers and Indicates Loss of PTEN as a Marker of Poor Prognosis. American Journal of Pathology, 2014, 184, 2671-2686.	3.8	29
76	Prognostic significance of phospho-histone H3 in prostate carcinoma. World Journal of Urology, 2014, 32, 703-707.	2.2	28
77	KDM5C Is Overexpressed in Prostate Cancer and Is a Prognostic Marker for Prostate-Specific Antigen-Relapse Following Radical Prostatectomy. American Journal of Pathology, 2014, 184, 2430-2437.	3.8	69
78	Prevention and early detection of prostate cancer. Lancet Oncology, The, 2014, 15, e484-e492.	10.7	372
79	Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma. Carcinogenesis, 2014, 35, 1636-1642.	2.8	66
80	CD74â€“NRG1 Fusions in Lung Adenocarcinoma. Cancer Discovery, 2014, 4, 415-422.	9.4	238
81	Rationale for co-targeting IGF-1R and ALK in ALK fusionâ€positive lung cancer. Nature Medicine, 2014, 20, 1027-1034.	30.7	243
82	Landscape of chromosome number changes in prostate cancer progression. World Journal of Urology, 2013, 31, 1489-1495.	2.2	14
83	SOX2 Expression Associates with Stem Cell State in Human Ovarian Carcinoma. Cancer Research, 2013, 73, 5544-5555.	0.9	129
84	Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer. Neoplasia, 2013, 15, 1-IN4.	5.3	205
85	Development and Clinical Validation of a Real-Time PCR Assay for PITX2 DNA Methylation to Predict Prostate-Specific Antigen Recurrence in Prostate Cancer Patients Following Radical Prostatectomy. Journal of Molecular Diagnostics, 2013, 15, 270-279.	2.8	53
86	Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3â€ERG gene rearrangement and an unfavorable clinical course. International Journal of Cancer, 2013, 132, 807-812.	5.1	39
87	Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Modern Pathology, 2013, 26, 1298-1306.	5.5	54
88	Activation of Invariant NK T Cells in Periodontitis Lesions. Journal of Immunology, 2013, 190, 2282-2291.	0.8	30
89	SOX2 Expression and Prognostic Significance in Ovarian Carcinoma. International Journal of Gynecological Pathology, 2013, 32, 358-367.	1.4	37
90	Role of the NK Cell-Activating Receptor CRACC in Periodontitis. Infection and Immunity, 2013, 81, 690-696.	2.2	32

#	Article	IF	Citations
91	Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer. Digestion, 2013, 88, 172-181.	2.3	25
92	Comparison of p40 (Î”‹scp›N‹/scp›p63) and p63 expression in prostate tissues â€“ which one is the superior diagnostic marker for basal cells?. Histopathology, 2013, 63, 50-56.	2.9	22
93	Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology, 2013, 63, 157-166.	2.9	41
94	Sex Determining Region Y-Box 2 (SOX2) Amplification Is an Independent Indicator of Disease Recurrence in Sinonasal Cancer. PLoS ONE, 2013, 8, e59201.	2.5	32
95	Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histology and Histopathology, 2013, 28, 605-10.	0.7	52
96	The peripheral zone of the prostate is more prone to tumor development than the transitional zone: Is the ETS family the key?. Molecular Medicine Reports, 2012, 5, 313-6.	2.4	41
97	Exome Enrichment and SOLiD Sequencing of Formalin Fixed Paraffin Embedded (FFPE) Prostate Cancer Tissue. International Journal of Molecular Sciences, 2012, 13, 8933-8942.	4.1	28
98	Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Modern Pathology, 2012, 25, 1473-1480.	5.5	118
99	Rationale for Treatment of Metastatic Squamous Cell Carcinoma of the Lung Using Fibroblast Growth Factor Receptor Inhibitors. Chest, 2012, 142, 1020-1026.	0.8	47
100	ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 157-162.	2.8	11
101	Differences in Frequency of ERG Oncoprotein Expression Between Index Tumors of Caucasian and African American Patients With Prostate Cancer. Urology, 2012, 80, 749-753.	1.0	73
102	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110.	21.4	1,186
103	Î±â€Methylacylâ€CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Followâ€up Study. Prostate, 2012, 72, 301-306.	2.3	9
104	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011, 1, 487-495.	9.4	725
105	Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology, 2011, 58, 1028-1036.	2.9	33
106	Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis. World Journal of Urology, 2011, 29, 451-456.	2.2	37
107	Validation of a TFE3 Break-apart FISH Assay for Xp11.2 Translocation Renal Cell Carcinomas. Diagnostic Molecular Pathology, 2011, 20, 129-137.	2.1	60
108	mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 2391-2396.	1.6	140

#	Article	IF	Citations
109	SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Modern Pathology, 2011, 24, 944-953.	5.5	177
110	Human prostate sphereâ€forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate, 2010, 70, 491-501.	2.3	130
111	ERG rearrangement in small cell prostatic and lung cancer. Histopathology, 2010, 56, 937-943.	2.9	64
112	An Oncogenic Role for ETV1 in Melanoma. Cancer Research, 2010, 70, 2075-2084.	0.9	107
113	Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer. Science Translational Medicine, 2010, 2, 62ra93.	12.4	761
114	Prevalence of TMPRSS2â€“ERG and SLC45A3â€“ERG gene fusions in a large prostatectomy cohort. Modern Pathology, 2010, 23, 539-546.	5.5	141
115	ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Modern Pathology, 2010, 23, 1061-1067.	5.5	114
116	ERG Rearrangement Metastasis Patterns in Locally Advanced Prostate Cancer. Urology, 2010, 75, 762-767.	1.0	56
117	ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression. Neoplasia, 2010, 12, 1031-IN22.	5.3	51
118	Aberrant Cytoplasmic Expression of p63 and Prostate Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 595-600.	2.5	60
119	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biology and Therapy, 2009, 8, 2042-2050.	3.4	78
120	Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States. Clinical Cancer Research, 2009, 15, 4706-4711.	7.0	205
121	In Situ Evidence of KRAS Amplification and Association With Increased p21 Levels in Nonâ€“Small Cell Lung Carcinoma. American Journal of Clinical Pathology, 2009, 132, 500-505.	0.7	24
122	Genome-Wide Linkage Analysis of TMPRSS2-ERG Fusion in Familial Prostate Cancer. Cancer Research, 2009, 69, 640-646.	0.9	32
123	Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?. Journal of Clinical Oncology, 2009, 27, 3459-3464.	1.6	329
124	Clinical significance of TTFâ€1 protein expression and TTFâ€1 gene amplification in lung adenocarcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 1977-1986.	3.6	98
125	Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochemical Pharmacology, 2009, 78, 1127-1138.	4.4	37
126	Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes and Cancer, 2009, 48, 366-380.	2.8	86

#	Article	IF	Citations
127	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics, 2009, 41, 1238-1242.	21.4	862
128	Detection of TMPRSS2-ERG Fusion Gene Expression in Prostate Cancer Specimens by a Novel Assay Using Branched DNA. Urology, 2009, 74, 1156-1161.	1.0	14
129	N-myc Downstream Regulated Gene 1 (NDRG1) Is Fused to ERG in Prostate Cancer. Neoplasia, 2009, 11, 804-W18.	5.3	105
130	An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2008, 21, 411-421.	2.0	27
131	Expression changes of CAV1 and EZH2, located on 7q31â^¼q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genetics and Cytogenetics, 2008, 182, 103-110.	1.0	22
132	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. Cancer Cell, 2008, 13, 519-528.	16.8	303
133	EML4-ALK Fusion Lung Cancer: A Rare Acquired Event. Neoplasia, 2008, 10, 298-302.	5.3	231
134	Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1682-1688.	2.5	19
135	Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. Journal of the National Cancer Institute, 2008, 100, 815-825.	6.3	286
136	Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications. Clinical Cancer Research, 2008, 14, 3380-3385.	7.0	200
137	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20007-20012.	7.1	927
138	TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion. American Journal of Surgical Pathology, 2007, 31, 882-888.	3.7	394
139	TMPRSS2-ERG Fusion Heterogeneity in Multifocal Prostate Cancer: Clinical and Biologic Implications. Urology, 2007, 70, 630-633.	1.0	146
140	Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Human Pathology, 2007, 38, 696-701.	2.0	388
141	Molecular Characterization of TMPRSS2-ERG Gene Fusion in the NCI-H660 Prostate Cancer Cell Line: A New Perspective for an Old Model. Neoplasia, 2007, 9, 200-IN3.	5.3	119
142	Characterizing the cancer genome in lung adenocarcinoma. Nature, 2007, 450, 893-898.	27.8	1,020
143	Prognostic factors in lymph node-positive prostate cancer. Urology, 2006, 67, 1016-1021.	1.0	41
144	TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. Cancer Research, 2006, 66, 8337-8341.	0.9	475

#	Article	IF	Citations
145	Imaging prostate cancer with 11C-choline PET/CT. Journal of Nuclear Medicine, 2006, 47, 1249-54.	5.0	191
146	Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science, 2005, 310, 644-648.	12.6	3,541
147	A Case of Sudden Cardiac Death Due to Isolated Eosinophilic Coronary Arteritis. Chest, 2005, 128, 1047-1050.	0.8	42
148	Quantifying Telomere Lengths of Human Individual Chromosome Arms by Centromere-Calibrated Fluorescence in Situ Hybridization and Digital Imaging. American Journal of Pathology, 2003, 163, 1751-1756.	3.8	92
149	A fatal case of necrotizing sinusitis due to toxigenic Corynebacterium ulcerans. International Journal of Medical Microbiology, 2002, 292, 59-63.	3.6	29
150	Differential and Mutually Exclusive Expression of CD95 and CD95 Ligand in Epithelia of Normal Pancreas and Chronic Pancreatitis. Laboratory Investigation, 2001, 81, 317-326.	3.7	17